Peanut Allergy Treatment Market Size & Growth Forecast 2026–2035, By Segments (Route of Administration, Distribution Channel, Drug Class), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growoth Outlook
Peanut Allergy Treatment Market size stood at USD 577.88 Million in 2025 and is predicted to grow at a 11.7% CAGR from 2026 to 2035, reaching USD 1.75 Billion by 2035. The industry revenue for 2026 is calculated at USD 638.23 million.
Get more details on this report
Request Free Sample ReportPeanut Allergy Treatment Market Intelligence Snapshot
Regional Market Dynamics
- North America accounted for 39.55% of the market in 2025, driven by established diagnosis pathways, broad specialist access, strong treatment awareness, and consistent adoption of clinically managed therapies.
- Asia Pacific is projected to grow at a 13.1% CAGR, supported by expanding healthcare infrastructure, greater specialist access, improved allergy recognition, and increasing adoption of structured clinical treatment.
Segment Momentum
- Injectable treatments accounted for 59.87% of the market in 2025 due to their established role in physician-supervised allergy care, particularly for acute intervention and clinically monitored treatment pathways.
- Retail pharmacy is the fastest-growing channel as patients increasingly seek convenient access to ongoing therapies and refill-based allergy treatment outside hospital-centered care environments.
Market Expansion Drivers
- Rising peanut allergy prevalence increasing demand for immunotherapy and emergency treatment solutions.
- Expansion of oral immunotherapy and biologics improving long-term allergy management outcomes.
- Increased pediatric allergy screening and diagnostic advancements expanding treated patient population.
Leading Market Participants
Global Market Forecast Snapshot
Market Outlook
Key players in the peanut allergy treatment market include Sanofi S.A. (France), Nestlé Health Science S.A. (Switzerland), DBV Technologies S.A. (France), ALK-Abelló A/S (Denmark), Genentech, Inc. (United States), Prota Therapeutics Pty Ltd. (Australia), Aravax Pty Ltd. (Australia), Camallergy Ltd. (United Kingdom), Stallergenes Greer International AG (Switzerland).Regional and Segment Outlook
North AmericaMarket Growth Drivers and Industry Trends
As diagnosed peanut allergy becomes more common, treatment decisions are shifting from avoidance-only strategies toward active clinical management, increasing demand for the peanut allergy treatment market. A larger patient pool increases routine prescribing of epinephrine rescue products while also pushing allergists, pediatricians, and caregivers to consider immunotherapy earlier, especially for children facing ongoing exposure risk in schools and shared food environments. This rise in case volume also changes provider behavior, with specialty clinics expanding capacity for supervised treatment initiation and follow-up, reinforcing market demand for both long-term desensitization options and emergency interventions used in day-to-day allergy management.
Expansion of oral immunotherapy and biologics improving long-term allergy management outcomes
The broader availability of oral immunotherapy and biologic-based approaches is reshaping the peanut allergy treatment market by making long-term management more clinically actionable rather than purely precautionary. Oral immunotherapy creates a structured treatment pathway that requires diagnosis, dose escalation, maintenance, and monitoring, which supports recurring product utilization and deeper engagement between patients and allergy specialists. At the same time, biologics are influencing market adoption by offering options for patients who may not tolerate conventional desensitization well or who need more individualized care, prompting providers to segment treatment choices more actively and encouraging market growth through a more diversified therapeutic landscape.
Increased pediatric allergy screening and diagnostic advancements expanding treated patient population
Earlier and more accurate identification of peanut allergy is enlarging the addressable base for the peanut allergy treatment market by moving more children from suspected allergy status into confirmed care pathways. Pediatric screening, component-resolved diagnostics, and improved referral patterns help clinicians distinguish true peanut allergy from sensitization alone, which reduces uncertainty around treatment eligibility and increases confidence in initiating immunotherapy or prescribing emergency medications. This practical shift matters because treatment uptake often depends on diagnosis clarity; as more children are identified before severe accidental exposures occur, physicians and families are more likely to pursue proactive management, contributing to market size growth through earlier intervention.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising peanut allergy prevalence increasing demand for immunotherapy and emergency treatment solutions | 2.00% | High | North America, Asia Pacific | High | Near Term |
| Expansion of oral immunotherapy and biologics improving long-term allergy management outcomes | 1.60% | High | North America, Europe | High | Mid Term |
| Increased pediatric allergy screening and diagnostic advancements expanding treated patient population | 1.40% | High | North America, Europe, Asia Pacific | Emerging | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America held a 39.55% share of the peanut allergy treatment market in 2025, backed by established allergy diagnosis pathways, broad specialist access, and earlier adoption of clinically managed treatment options. The region’s leadership is strengthened by a healthcare environment where patients are more likely to move from diagnosis to active treatment under allergist supervision, which sustains prescription volumes and follow-up care. Strong awareness among caregivers and clinicians also supports routine identification of peanut allergy cases, helping maintain steady demand through formal treatment channels rather than reliance on avoidance strategies alone.
Asia Pacific is projected to expand at a 13.1% CAGR over the forecast period, driven by improving recognition of food allergies and a gradual shift toward structured clinical management in larger healthcare markets across the region. Growth in the peanut allergy treatment market is being impelled by rising access to specialist care, expanding urban healthcare infrastructure, and increasing willingness among families to seek intervention beyond basic dietary avoidance. As diagnosis becomes more consistent and treatment availability broadens, adoption is accelerating in practice through greater engagement with hospital-based and specialist-led allergy care.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Specialized Care PathwaysGermany is strengthening allergy management through specialist clinics and standardized treatment protocols for peanut allergy patients. Demand in Germany increasingly centers on therapies that can be integrated into supervised care programs and long-term patient monitoring.
France 🇫🇷
Structured Allergy ProgramsFrance supports peanut allergy treatment through coordinated care models involving allergists and patient education initiatives. Interest in France is growing for therapies that can complement dietary management and reduce the risk of severe allergic reactions.
Italy 🇮🇹
Patient Monitoring FocusItaly's peanut allergy treatment market is characterized by increasing attention to long-term patient monitoring and individualized care strategies. Healthcare providers in Italy are seeking treatment approaches that improve adherence and support safer management of food allergy risks.
Japan 🇯🇵
Pediatric Management EmphasisJapan is placing greater attention on pediatric food allergy management, creating opportunities for treatments that reduce the burden on affected families. Healthcare stakeholders in Japan are carefully evaluating therapies that demonstrate safety and support gradual desensitization approaches.
South Korea 🇰🇷
Clinical Awareness ExpansionSouth Korea is experiencing rising clinical attention toward food allergies and improved identification of peanut-sensitive patients. The market in South Korea is increasingly focused on expanding access to therapeutic options and strengthening physician education around allergy management.
United States 🇺🇸
Early Intervention AdoptionThe U.S. peanut allergy treatment market is benefiting from growing awareness of food allergies and increased acceptance of therapeutic interventions for pediatric patients. Healthcare providers in the U.S. are focusing on earlier diagnosis and structured treatment pathways that improve long-term management.
Segment Leadership and Growth Trends
Peanut Allergy Treatment Market Share (%), Route of Administration, 2025
Go beyond the chart, access full insights & data tables
Request Free Sample ReportWithin the peanut allergy treatment market, Injectable held the leading position in 2025 with a 59.87% share. Its leadership is supported by the established role of physician-directed treatment pathways in allergy care, especially where controlled dosing, acute intervention needs, and clinical supervision remain central to patient management. Injectable formats also align well with hospital and specialist prescribing patterns, which helps sustain their share across cases where reliability, speed of administration, and established treatment protocols are prioritized.
Oral is the fastest-growing route of administration in the peanut allergy treatment market as demand shifts toward treatment approaches that fit more easily into ongoing, day-to-day management. Growth is being supported by rising interest in less invasive administration and by the practical appeal of therapies that can be integrated into longer-term care outside procedure-based settings. Compared with injectable options, oral treatment is gaining momentum because it better matches evolving patient and caregiver preferences for convenience and routine adherence in allergy management.
Distribution Channel Segment Analysis: Hospital Pharmacy (Largest Segment) vs Retail Pharmacy (Fastest-Growing Segment)
Hospital Pharmacy accounted for the largest position in the peanut allergy treatment market in 2025, holding a 58.23% share. This channel’s leadership reflects the clinical nature of peanut allergy treatment, where diagnosis, initiation of therapy, and management of adverse reactions often remain closely tied to hospital-based care environments. Hospital pharmacies benefit from direct integration with allergists, pediatric specialists, and monitored treatment settings, which helps preserve their share in dispensing therapies that require tighter oversight and coordinated care.
Retail Pharmacy is the fastest-growing distribution channel in the peanut allergy treatment market, influenced by the increasing need for easier access to ongoing therapy and refill-based treatment models. Its momentum comes from the practical advantage of broader consumer reach and greater convenience for patients managing peanut allergy treatment outside hospital settings. Relative to hospital pharmacy channels, retail pharmacy is expanding faster because it is better positioned to support routine access, repeat dispensing, and more decentralized treatment follow-through.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Route of Administration | Oral, Injectable, Others | Injectable | Oral |
| Distribution Channel | Hospital Pharmacy, Retail Pharmacy, Others | Hospital Pharmacy | Retail Pharmacy |
| Drug Class | Antihistamines, Epinephrine, Immunotherapies, Others | Epinephrine | Immunotherapies |
Competitive Landscape and Market Positioning
1. Sanofi S.A. (France)
2. Nestlé Health Science S.A. (Switzerland)
3. DBV Technologies S.A. (France)
4. ALK-Abelló A/S (Denmark)
5. Genentech Inc. (United States)
6. Prota Therapeutics Pty Ltd. (Australia)
7. Aravax Pty Ltd. (Australia)
8. Camallergy Ltd. (United Kingdom)
9. Stallergenes Greer International AG (Switzerland)
Rising incidence of food allergies is accelerating innovation in immunotherapy and desensitization treatments. The peanut allergy treatment market is evolving through development of targeted biological approaches that reduce allergic response severity. Clinical research advancements are improving treatment safety and efficacy profiles. Expanding therapeutic pipelines are also enhancing long-term management options for patients.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| No companies available. | |||||||
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Novartis | Mar-26 | Novartis entered a definitive agreement to acquire Excellergy, Inc. in a deal valued at up to $2 billion, expected to close in the second half of 2026. The acquisition adds the lead asset Exl-111, a next-generation anti-IgE antibody, to Novartis' immunology portfolio, strengthening its strategic position in food allergy therapeutics and other IgE-driven disease indications. |
| DBV Technologies | Jun-26 | DBV Technologies initiated the THRIVE Phase 2 clinical study to evaluate the efficacy and safety of the Viaskin Peanut patch in infants aged 6 through 12 months. This expansion of the clinical program into younger populations aims to investigate early intervention strategies for modifying the long-term trajectory of peanut allergy and achieving ad-lib peanut consumption. |
| Aravax | Apr-26 | Aravax strengthened its leadership team with the appointment of new board members Carsten Hellmann and Andrew Oxtoby to support its transition toward Phase 3 clinical development. The company continues to advance its lead peptide-based immunotherapy candidate, PVX108, which is currently undergoing international Phase 2 trials to assess its potential as a safer, disease-modifying treatment for peanut allergy. |
| Regeneron | Feb-26 | Regeneron presented new clinical data highlighting the impact of its immunology portfolio at the AAAAI Annual Meeting. The company continues to study the role of biologics like Dupilumab in managing type 2 inflammation-driven conditions, including analyses of sensitization to common food allergens like peanuts in pediatric populations with atopic dermatitis, supporting its ongoing research into broad allergy therapeutic paradigms. |
Explore This Report
Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.
Peanut Allergy Treatment Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| No segment data available. | |
Peanut Allergy Treatment Market — report.custom
| Custom Chapter | Custom Details | ||
|---|---|---|---|
| No custom TOC data available. | |||
Need a different cut of the data?
Request Custom ResearchHow much revenue does the peanut allergy treatment market generate?
What is the forecasted size of the peanut allergy treatment industry?
How is the expansion of oral immunotherapy influencing treatment adoption in the peanut allergy treatment market?
Why is earlier diagnosis becoming strategically important in the peanut allergy treatment market?
Why do injectable treatments dominate the peanut allergy treatment market?
Which distribution channel is growing fastest in the peanut allergy treatment market?
What supports North America's leadership in the peanut allergy treatment market?
Why is Asia Pacific the fastest-growing regional market for peanut allergy treatment?
What are the prominent companies operating in the peanut allergy treatment landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source Category | Research Sources | Purpose |
|---|---|---|
| Government Publications | Government agencies, statistical departments, regulatory bodies | Industry statistics, regulatory insights, and policy analysis |
| Company Disclosures | Annual reports, investor presentations, financial filings | Company performance, business strategy, and market positioning |
| Trade Associations | Industry associations and professional organizations | Industry developments, standards, and market perspectives |
| Technical Literature | Research papers, technical publications, academic journals | Technology developments and technical validation |
| Patent Analysis | Patent databases and intellectual property publications | Innovation trends, technology activity, and competitive research |
| Industry Databases | Established research databases and market intelligence resources | Market benchmarking, historical data, and industry analysis |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization